Welcome to our dedicated page for Artiva Biotherapeutics SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics, Inc. reported that Chief Tech Operations Officer Christopher Horan sold 7,002 shares of common stock on May 19, 2026 at a weighted average price of $9.0078 per share. The price range for these sales was between $8.7421 and $9.0104.
According to the company’s sell-to-cover policy, these automatic sales were made solely to cover tax withholding obligations arising from the vesting and release of restricted stock units, and were not discretionary trades. After the transaction, Horan directly owned 293,450 shares of Artiva common stock.
Artiva Biotherapeutics COO Jennifer Bush reported an automatic sale of 8,790 common shares to cover tax withholding on vested restricted stock units. The shares were sold in the open market at a weighted average price of $9.0078 per share, within a range of $8.7439 to $9.0104. After this sell-to-cover transaction under the company’s tax policy, she continues to hold 337,920 shares directly.
Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, sold 7,037 shares of common stock in an open-market transaction at a weighted average price of $9.0076 per share. The company explains these automatic sales were made solely to cover tax withholding obligations tied to vested restricted stock units. Following the sale, Banerjee directly holds 144,963 shares.
Artiva Biotherapeutics, Inc. Chief Executive Officer Fred Aslan reported an open-market sale of 27,116 shares of common stock at a weighted average price of $9.0077 per share. After this transaction, he directly holds 1,535,082 shares.
The company has a “sell-to-cover” policy for tax withholding on vesting restricted stock units, and these shares were sold automatically to cover related tax obligations, not at Aslan’s discretion. Sale prices ranged between $8.7383 and $9.0104.
Artiva Biotherapeutics President & Head of R&D Diego Miralles received new equity awards. He was granted 77,500 shares of common stock as restricted stock units and 232,500 employee stock options with an exercise price of $9.22 per share under the company’s 2025 Inducement Plan.
Following the grants, he directly holds 77,500 shares of common stock and 232,500 options. According to the award terms, 25% of the option shares vest on May 15, 2027, with the remaining shares vesting monthly over the next 36 months.
Artiva Biotherapeutics announced several leadership changes and a new executive compensation package. On May 18, 2026, Diego Miralles, M.D. resigned from the Board and was appointed President and Head of Research and Development, reducing the Board size from eight to seven members. That same day, the company and Chief Financial Officer Thad Huston agreed to his separation, effective May 22, 2026; he will receive about $135,000 (three months of base salary) and up to nine months of COBRA health coverage under a separation agreement.
On the effective date, CEO Fred Aslan, M.D. was also appointed principal financial officer and principal accounting officer while remaining CEO and a director. Under an offer letter, Dr. Miralles will receive a $600,000 annual base salary, a discretionary annual bonus targeted at 45% of salary, options to purchase 232,500 shares, and 77,500 restricted stock units, all vesting over four years. The offer includes non–change-of-control and change-of-control severance protections that provide salary continuation, COBRA coverage, bonus eligibility and equity vesting acceleration if specified termination conditions are met.
ARTV reported a proposed sale of 3,500 shares of Common Stock via a Form 144 notice. The shares relate to Restricted Stock Units that vested on 05/15/2026 and are described as compensation for services rendered. The broker listed is Morgan Stanley Smith Barney LLC.
ARTV submitted a Rule 144 notice for 7,500 shares of Common Stock associated with Restricted Stock Units vesting under a registered plan. The RSUs vested on 05/15/2026 and the form lists 05/18/2026 in the securities line. The filing lists the transaction as compensation for services rendered to the issuer.
ARTV submitted a Form 144 notice to sell 9,000 shares of Common Stock. The filing lists 05/15/2026 as the vesting date for Restricted Stock Units issued as compensation for services rendered, and the broker listed is Morgan Stanley Smith Barney LLC. The filing date shown is 05/18/2026 and the shares trade on NASDAQ.
ARTV reported a proposed sale of 7,000 shares of Common Stock under Rule 144. The filing lists these shares as Restricted Stock Units vesting under a registered plan on 05/15/2026 and identifies Morgan Stanley Smith Barney LLC as broker.
The excerpt also shows 64,540 shares sold in the past three months and a separate figure of 48,588,198 tied to the filing line dated 05/18/2026.